Bragar Eagel & Squire, P.C. Litigation Partners Encourage Investors Who Suffered Losses In Semler Scientific (SMLR) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Semler and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Bragar Eagel & Squire, P.C., a nationally recognized st ...

NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- If you have suffered a loss on your Semler Scientific, Inc. (“Semler” or the “Company”) (NASDAQ:SMLR) investment, contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost. Investors have until October 28, 2025 to ask the Court to appoint them as lead plaintiff. [CONTACT THE FIRM IF YOU SUFFERED A LOSS] What Hap ...

Core Viewpoint - Semler Scientific, Inc. is facing a securities fraud class action lawsuit due to alleged misleading statements regarding a Department of Justice investigation into the company's reimbursement claims related to the QuantaFlo device [3][5]. Group 1: Company Background and Events - On February 28, 2025, Semler disclosed in its Form 10-K that it received a civil investigative demand from the DOJ in July 2017 concerning its reimbursement claims [3]. - Following unsuccessful settlement discussions with the DOJ in February 2025, Semler's share price fell by approximately 9.39%, from $42.92 to $38.89 [3]. - On April 15, 2025, Semler announced a settlement agreement of $29.75 million to resolve all claims, leading to a further decline in share price by about 9.9%, from $34.40 to $31.00 [4]. Group 2: Lawsuit Details - The class action lawsuit is on behalf of investors who purchased Semler securities from March 10, 2021, to April 15, 2025, alleging that the company made false or misleading statements regarding the DOJ investigation [5]. - The lawsuit claims that the company failed to disclose material information about the investigation, which resulted in investor damages when the truth was revealed [5].

Core Viewpoint - Semler Scientific Inc. is facing a class action lawsuit due to alleged securities fraud related to undisclosed investigations by the U.S. Department of Justice regarding its QuantaFlo device and reimbursement claims [2][4]. Summary by Sections Company Background - Semler Scientific Inc. (NASDAQ: SMLR) is involved in the development of medical devices, specifically the QuantaFlo device for peripheral artery disease [2]. Legal Developments - On February 28, 2025, Semler disclosed a potential risk of a civil lawsuit from the DOJ regarding its reimbursement claims, which led to a significant drop in its stock price [2][3]. - Following unsuccessful settlement discussions with the DOJ in February 2025, Semler announced on April 15, 2025, an agreement in principle to pay $29.75 million to settle all claims, resulting in another decline in stock price [3]. Stock Performance - After the February 28 announcement, Semler's stock fell by $4.03, or 9.4%, closing at $38.89 on March 3, 2025 [3]. - Following the April 15 announcement, the stock dropped by $3.40, or 9.9%, closing at $31.00 on April 16, 2025 [3]. Allegations in the Lawsuit - The class action lawsuit alleges that Semler made materially false and misleading statements and failed to disclose a DOJ investigation into violations of the False Claims Act, which misled investors about the company's business prospects [4].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Semler Scientific Inc. for possible violations of federal securities laws and unlawful business practices [1][3]. Company Investigation - Semler Scientific Inc. disclosed in its Form 10-K filed on February 28, 2025, that it received a civil investigative demand from the U.S. Department of Justice (DOJ) in July 2017 regarding reimbursement claims related to its QuantaFlo device [3]. - The company has faced multiple requests for information from the DOJ over the years, with the most recent being in April 2023 [3]. - Settlement discussions with the DOJ in February 2025 were unsuccessful, and there is a risk of a civil False Claims Act lawsuit being filed against Semler [3]. Stock Performance - Following the news of the DOJ investigation and potential lawsuit, Semler's stock price fell by $4.03, from $42.92 on February 28, 2025, to $38.89 on March 3, 2025 [3].

Core Viewpoint - The Department of Justice is investigating UnitedHealth for allegedly encouraging staff to make specific diagnoses that would lead to higher Medicare payments, particularly under the Medicare Advantage program [1][6]. Investigation Details - The investigation involves inquiries from the Justice Department, FBI, and Health and Human Services regarding patient testing, diagnostic procedures, and the process of sending nurses to patients' homes [2]. - Former employees reported that investigators asked about training related to making diagnoses and the methods used to contact patients for testing [4][8]. Company Response - UnitedHealth maintains that it supports the integrity of its Medicare Advantage business and welcomes regular reviews of its practices [3]. - The company criticized the Wall Street Journal for what it perceives as a biased narrative against Medicare Advantage, claiming reliance on incomplete data [3][4]. Diagnostic Practices - Former doctors indicated that the focus was on coding practices, specifically how diagnosis codes are submitted to Medicare for payments [5]. - Investigators inquired about bonuses for doctors reviewing potential diagnoses suggested by UnitedHealth [7]. Software and Tools - The investigation also looked into the "diagnosis cart" feature of UnitedHealth's software, which suggests potential medical conditions to nurses [11]. - UnitedHealth argues that its diagnostic practices are aimed at early disease detection and plans to implement independent third-party oversight for these practices [8]. Previous Investigations - A separate decade-long effort by the Justice Department to recover alleged Medicare overpayments from UnitedHealth was unsuccessful [10].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Semler Scientific Inc. and its officers or directors [1] Group 1: Legal Investigation - Pomerantz LLP is representing investors of Semler Scientific Inc. in an investigation regarding possible securities fraud [1] - The investigation follows Semler's disclosure of a risk related to a potential complaint from the U.S. Department of Justice regarding the company's reimbursement claims for its QuantaFlo device [3] Group 2: Financial Impact - Following the news of the investigation and the DOJ's involvement, Semler's stock price dropped by $4.03, or 9.4%, closing at $38.89 per share on March 3, 2025 [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Semler Scientific Inc. and its officers or directors [1] Company Summary - Semler Scientific Inc. filed its annual report for 2024 on February 28, 2025, indicating a risk of a civil complaint from the U.S. Department of Justice related to the False Claims Act [3] - The company received an initial civil investigative demand from the DOJ in July 2017 concerning reimbursement claims for its QuantaFlo device [3] - Settlement discussions with the DOJ in February 2025 were unsuccessful [3] Market Reaction - Following the news of the investigation and potential legal issues, Semler's stock price dropped by $4.03 per share, or 9.4%, closing at $38.89 per share on March 3, 2025 [4]

Core Viewpoint - Pomerantz LLP is investigating claims on behalf of investors of Semler Scientific Inc. regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1]. Group 1: Company Disclosure - On February 28, 2025, Semler filed its annual report for 2024, indicating a risk of a complaint from the U.S. Department of Justice (DOJ) related to a civil False Claims Act lawsuit [3]. - Semler disclosed receiving an initial civil investigative demand from the DOJ in July 2017 concerning reimbursement claims for its QuantaFlo device [3]. - The company participated in unsuccessful settlement discussions with the DOJ in February 2025 [3]. Group 2: Market Reaction - Following the news of the DOJ investigation, Semler's stock price dropped by $4.03 per share, or 9.4%, closing at $38.89 per share on March 3, 2025 [4].

Core Viewpoint - Semler Scientific Inc. is under investigation for potential violations of federal securities laws and unlawful business practices, particularly concerning its QuantaFlo device reimbursement claims [1][2]. Company Summary - Semler filed its Form 10-K with the SEC on February 28, 2025, revealing an initial civil investigative demand from the U.S. Department of Justice (DOJ) dating back to July 2017 [2]. - The company has faced multiple requests for information from the DOJ, with significant dates including February 2019, December 2021, April 2022, and April 2023 [2]. - Settlement discussions with the DOJ in February 2025 were unsuccessful, leading to concerns that the DOJ may file a civil False Claims Act lawsuit against Semler [2]. - Following the news of the investigation, Semler's share price dropped from $42.92 to $38.89, a decline of $4.03 per share, between February 28 and March 3, 2025 [2]. Legal Context - Bragar Eagel & Squire, P.C. is investigating potential claims on behalf of Semler stockholders regarding the company's legal issues [1]. - The law firm specializes in representing investors in complex litigation, including securities and derivative cases [4].